Highlights From the American Diabetes Association Scientific Session 2023
JAMA Medical News
English - July 12, 2023 15:00 - 12 minutes - 28.9 MB - ★★★★ - 56 ratingsMedicine Health & Fitness Science jama medicine news publichealth Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Worsening US Maternal Death Rates
Next Episode: July 2023 Medical News Summary
Data on a new crop of hormone analogues for weight loss—including an oral version of semaglutide and the triple agent retatrutide—were recently presented at the American Diabetes Association’s annual Scientific Sessions. Robert Gabbay, MD, PhD, the ADA’s chief scientific and medical officer, speaks with JAMA’s Jennifer Abbasi about this and other clinical data presented at the meeting.
Related Content: